Belldegrun Arie's Form 4 filing
LB Pharmaceuticals Inc (LBRX) · filed Sep 16, 2025
- Accession no.
- 0001193125-25-204935
- Filed
- Sep 16, 2025, 3:46 PM ET
- Trade date
- Sep 12, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market purchases total $5.00M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Belldegrun ArieCIK 0001296549 | 10% Owner |
| Vida Ventures GP III, L.L.C.CIK 0001855502 | 10% Owner |
| Vida Ventures III-A, L.P.CIK 0001855503 | 10% Owner |
| Vida Ventures III, L.P.CIK 0001855504 | 10% Owner |
| Vida Ventures Management Co. LLCCIK 0001905615 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2025 | Common Stock | CConversionAcquired | +547,648 | –F1 | – | 547,648 | Indirect | |
| Sep 12, 2025 | Common Stock | CConversionAcquired | +1,262 | –F1 | – | 1,262 | Indirect | |
| Sep 12, 2025 | Common Stock | PPurchaseAcquired | +332,566 | $15.00 | +$4,988,490 | 880,214 | Indirect | |
| Sep 12, 2025 | Common Stock | PPurchaseAcquired | +767 | $15.00 | +$11,505 | 2,029 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2025 | Common Stock | CConversionDisposed | −547,648 | $0.00 | $0 | 0 | Indirect | |
| Sep 12, 2025 | Common Stock | CConversionDisposed | −1,262 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.
Referenced by the price of 2 transactions in Table I.